{
    "organizations": [],
    "uuid": "ecd351ae32b6ab511b2fe3597708ad89d935eefc",
    "author": "",
    "url": "https://www.reuters.com/article/brief-tetraphase-pharmaceuticals-announc/brief-tetraphase-pharmaceuticals-announces-submission-of-nda-to-fda-for-eravacycline-to-treat-intra-abdominal-infections-idUSASB0BZI9",
    "ord_in_thread": 0,
    "title": "BRIEF-Tetraphase Pharmaceuticals Announces Submission Of NDA To FDA For Eravacycline To Treat Intra-Abdominal Infections",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 2, 2018 / 9:39 PM / Updated 22 minutes ago BRIEF-Tetraphase Pharmaceuticals Announces Submission Of NDA To FDA For Eravacycline To Treat Intra-Abdominal Infections Reuters Staff 1 Min Read \nJan 2 (Reuters) - Tetraphase Pharmaceuticals Inc: \n* TETRAPHASE PHARMACEUTICALS ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION TO FDA FOR ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI) \n* TETRAPHASE PHARMACEUTICALS INC - NDA SUBMISSION INCLUDES DATA FROM IGNITE1 AND IGNITE 4 PHASE 3 CLINICAL TRIALS Source text for Eikon: Further company coverage:",
    "published": "2018-01-02T23:39:00.000+02:00",
    "crawled": "2018-01-03T00:06:10.055+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "updated",
        "minute",
        "ago",
        "pharmaceutical",
        "announces",
        "submission",
        "nda",
        "fda",
        "eravacycline",
        "treat",
        "infection",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "tetraphase",
        "pharmaceutical",
        "inc",
        "tetraphase",
        "pharmaceutical",
        "announces",
        "submission",
        "new",
        "drug",
        "application",
        "fda",
        "eravacycline",
        "treatment",
        "complicated",
        "infection",
        "ciai",
        "tetraphase",
        "pharmaceutical",
        "inc",
        "nda",
        "submission",
        "includes",
        "data",
        "ignite1",
        "ignite",
        "phase",
        "clinical",
        "trial",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}